172931-93-0

Basic information

• Product Name: CHEMBRDG-BB 6523984
• Synonyms: CHEMBRDG-BB 6523984;4-(2-NAPHTHYLMETHOXY)BENZALDEHYDE;4-(2-naphthylmethoxy)benzaldehyde(SALTDATA: FREE)
• CAS NO: 172931-93-0
• Molecular Formula: C₁₈H₁₄O₂
• Molecular Weight: 262.3
• Mol File: 172931-93-0.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 459.6°C at 760 mmHg
• Flash Point: 214.5°C
• Appearance: /
• Density: 1.192g/cm³
• Vapor Pressure: 1.25E-08mmHg at 25°C
• Refractive Index: 1.668
• CAS DataBase Reference: CHEMBRDG-BB 6523984(CAS DataBase Reference)
• NIST Chemistry Reference: CHEMBRDG-BB 6523984(172931-93-0)
• EPA Substance Registry System: CHEMBRDG-BB 6523984(172931-93-0)

Safety Data

• Hazardous Substances Data: 172931-93-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C18H14O2/c19-12-14-6-9-18(10-7-14)20-13-15-5-8-16-3-1-2-4-17(16)11-15/h1-12H,13H2

Upstream product

• 123-08-0 4-hydroxy-benzaldehyde 
• 131340-67-5 3-(naphth-2-ylmethoxy)benzaldehyde 
• 939-26-4 2-bromomethylnaphthyl bromide 
• 2506-41-4 1-chloromethylnaphthalene 

Relevant articles and documents

Development of hydroxy-based sphingosine kinase inhibitors and anti-inflammation in dextran sodium sulfate induced colitis in mice

Sphingosine kinase (SphK)-catalyzed production of sphingosine-1-phosphate (S1P) regulates cell growth, survival and proliferation as well as inflammatory status in animals. In recent study we reported the N′-(3-(benzyloxy)benzylidene)-3,4,5-trihydroxybenzohydrazide scaffold as a potent SphK inhibitor. As a continuation of these efforts, 51 derivatives were synthesized and evaluated by SphK1/2 inhibitory activities for structure-activity relationship (SAR) study. Among them, 33 was identified as the most potent SphK inhibitor. Potency of 33 was also observed to efficiently decrease SphK1/2 expression in human colorectal cancer cells (HCT116) and significantly inhibit dextran sodium sulfate (DSS)-induced colitis as well as the decreased expression of interleukin (IL)-6 and cyclooxygenase-2 (COX-2) in mouse models. Collectively, 33 was validated as an effective SphK inhibitor, which can be served as anti-inflammatory agent to probably treat inflammatory bowel diseases in human.

BENZYLIDENE RHODANINES

This invention provides novel benzylidene rhodanines which are useful as agents in treating or preventing conditions associated with . beta.-amyloid peptide. This invention further provides methods of treating or preventing Alzheimer's Disease which comprises administering to a mammal in need thereof an effective amount of one or more of the benzylidene rhodanines of the present invention.